Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2010 (2010), Article ID 485468, 11 pages
http://dx.doi.org/10.1155/2010/485468
Research Article

Cytokines and Growth Factors Stimulate Hyaluronan Production: Role of Hyaluronan in Epithelial to Mesenchymal-Like Transition in Non-Small Cell Lung Cancer

1Lung Cancer Biology Laboratory, Department of Biochemistry, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA
2Lung Cancer Biology Laboratory, Department of Internal Medicine, Rush University Medical Center, 1735 West Harrison Street, Chicago, IL 60612, USA

Received 31 July 2009; Revised 23 March 2010; Accepted 5 May 2010

Academic Editor: Anne Hamburger

Copyright © 2010 Geraldine Chow et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. T. Greenlee, T. Murray, S. Bolden, and P. A. Wingo, “Cancer statistics, 2000,” CA: A Cancer Journal for Clinicians, vol. 50, no. 1, pp. 7–33, 2000. View at Google Scholar · View at Scopus
  2. R. Pirinen, R. Tammi, M. Tammi et al., “Prognostic value of hyaluronan expression in non-small-cell lung cancer: increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma,” International Journal of Cancer, vol. 95, no. 1, pp. 12–17, 2001. View at Google Scholar
  3. B. P. Toole, “Hyaluronan: from extracellular glue to pericellular cue,” Nature Reviews Cancer, vol. 4, no. 7, pp. 528–539, 2004. View at Google Scholar · View at Scopus
  4. N. Itano and K. Kimata, “Mammalian hyaluronan synthases,” IUBMB Life, vol. 54, no. 4, pp. 195–199, 2002. View at Publisher · View at Google Scholar · View at Scopus
  5. P. H. Weigel, V. C. Hascall, and M. Tammi, “Hyaluronan synthases,” Journal of Biological Chemistry, vol. 272, no. 22, pp. 13997–14000, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. N. Itano, T. Sawai, M. Yoshida et al., “Three isoforms of mammalian hyaluronan synthases have distinct enzymatic properties,” Journal of Biological Chemistry, vol. 274, no. 35, pp. 25085–25092, 1999. View at Publisher · View at Google Scholar · View at Scopus
  7. S. Adamia, C. A. Maxwell, and L. M. Pilarski, “Hyaluronan and hyaluronan synthases: potential therapeutic targets in cancer,” Current Drug Targets—Cardiovascular and Haematological Disorders, vol. 5, no. 1, pp. 3–14, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Berdiaki, A. Zafiropoulos, E. Fthenou et al., “Regulation of hyaluronan and versican deposition by growth factors in fibrosarcoma cell lines,” Biochimica et Biophysica Acta, vol. 1780, no. 2, pp. 194–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. G. N. Tzanakakis, N. K. Karamanos, and A. Hjerpe, “Effects on glycosaminoglycan synthesis in cultured human mesothelioma cells of transforming, epidermal, and fibroblast growth factors and their combinations with platelet-derived growth factor,” Experimental Cell Research, vol. 220, no. 1, pp. 130–137, 1995. View at Publisher · View at Google Scholar · View at Scopus
  10. L. Y. W. Bourguignon, E. Gilad, and K. Peyrollier, “Heregulin-mediated ErbB2-ERK signaling activates hyaluronan synthases leading to CD44-dependent ovarian tumor cell growth and migration,” Journal of Biological Chemistry, vol. 282, no. 27, pp. 19426–19441, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Anttila, R. H. Tammi, M. I. Tammi, K. J. Syrjänen, S. V. Saarikoski, and V.-M. Kosma, “High levels of stromal hyaluronan predict poor disease outcome in epithelial ovarian cancer,” Cancer Research, vol. 60, no. 1, pp. 150–155, 2000. View at Google Scholar · View at Scopus
  12. P. Auvinen, R. Tammi, J. Parkkinen et al., “Hyaluronan in peritumoral stroma and malignant cells associates with breast cancer spreading and predicts survival,” American Journal of Pathology, vol. 156, no. 2, pp. 529–536, 2000. View at Google Scholar · View at Scopus
  13. K. Kimata, Y. Honma, M. Okayama, K. Oguri, M. Hozumi, and S. Suzuki, “Increased synthesis of hyaluronic acid by mouse mammary carcinoma cell variants with high metastatic potential,” Cancer Research, vol. 43, no. 3, pp. 1347–1354, 1983. View at Google Scholar
  14. T. Asplund, M. A. Versnel, T. C. Laurent, and P. Heldin, “Human mesothelioma cells produce factors that stimulate the production of hyaluronan by mesothelial cells and fibroblasts,” Cancer Research, vol. 53, no. 2, pp. 388–392, 1993. View at Google Scholar · View at Scopus
  15. R. Kosaki, K. Watanabe, and Y. Yamaguchi, “Overproduction of hyaluronan by expression of the hyaluronan synthase Has2 enhances anchorage-independent growth and tumorigenicity,” Cancer Research, vol. 59, no. 5, pp. 1141–1145, 1999. View at Google Scholar · View at Scopus
  16. N. Liu, F. Gao, Z. Han, X. Xu, C. B. Underhill, and L. Zhang, “Hyaluronan synthase 3 overexpression promotes the growth of TSU prostate cancer cells,” Cancer Research, vol. 61, no. 13, pp. 5207–5214, 2001. View at Google Scholar · View at Scopus
  17. A. Jacobson, M. Rahmanian, K. Rubin, and P. Heldin, “Expression of hyaluronan synthase 2 or hyaluronidase 1 differentially affect the growth rate of transplantable colon carcinoma cell tumors,” International Journal of Cancer, vol. 102, no. 3, pp. 212–219, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. N. Itano, T. Sawai, O. Miyaishi, and K. Kimata, “Relationship between hyaluronan production and metastatic potential of mouse mammary carcinoma cells,” Cancer Research, vol. 59, no. 10, pp. 2499–2504, 1999. View at Google Scholar · View at Scopus
  19. M. A. Simpson, C. M. Wilson, and J. B. McCarthy, “Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice,” American Journal of Pathology, vol. 161, no. 3, pp. 849–857, 2002. View at Google Scholar · View at Scopus
  20. L. Udabage, G. R. Brownlee, M. Waltham et al., “Antisense-mediated suppression of hyaluronan synthase 2 inhibits the tumorigenesis and progression of breast cancer,” Cancer Research, vol. 65, no. 14, pp. 6139–6150, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Y. W. Bourguignon, K. Peyrollier, E. Gilad, and A. Brightman, “Hyaluronan-CD44 interaction with neural Wiskott-Aldrich syndrome protein (N-WASP) promotes actin polymerization and ErbB2 activation leading to β-catenin nuclear translocation, transcriptional up-regulation, and cell migration in ovarian tumor cells,” Journal of Biological Chemistry, vol. 282, no. 2, pp. 1265–1280, 2007. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Ohwada, C. Nakaseko, M. Koizumi et al., “CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells,” European Journal of Haematology, vol. 80, no. 3, pp. 245–250, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. R. Ohashi, F. Takahashi, R. Cui et al., “Interaction between CD44 and hyaluronate induces chemoresistance in non-small cell lung cancer cell,” Cancer Letters, vol. 252, no. 2, pp. 225–234, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Alaniz, M. García, P. Cabrera et al., “Modulation of matrix metalloproteinase-9 activity by hyaluronan is dependent on NF-κB activity in lymphoma cell lines with dissimilar invasive behavior,” Biochemical and Biophysical Research Communications, vol. 324, no. 2, pp. 736–743, 2004. View at Publisher · View at Google Scholar · View at Scopus
  25. Y. Zhang, A. A. Thant, K. Machida et al., “Hyaluronan-CD44s signaling regulates matrix metalloproteinase-2 secretion in a human lung carcinoma cell line QG90,” Cancer Research, vol. 62, no. 14, pp. 3962–3965, 2002. View at Google Scholar · View at Scopus
  26. J. P. Thiery, “Epithelial-mesenchymal transitions in tumor progression,” Nature Reviews Cancer, vol. 2, no. 6, pp. 442–454, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. H. Hugo, M. L. Ackland, T. Blick et al., “Epithelial—mesenchymal and mesenchymal—epithelial transitions in carcinoma progression,” Journal of Cellular Physiology, vol. 213, no. 2, pp. 374–383, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. R. M. Bremnes, R. Veve, F. R. Hirsch, and W. A. Franklin, “The E-cadherin cell-cell adhesion complex and lung cancer invasion, metastasis, and prognosis,” Lung Cancer, vol. 36, no. 2, pp. 115–124, 2002. View at Publisher · View at Google Scholar · View at Scopus
  29. G. Deeb, J. Wang, N. Ramnath et al., “Altered E-cadherin and epidermal growth factor receptor expressions are associated with patient survival in lung cancer: a study utilizing high-density tissue microarray and immunohistochemistry,” Modern Pathology, vol. 17, no. 4, pp. 430–439, 2004. View at Publisher · View at Google Scholar · View at Scopus
  30. S. Loric, V. Paradis, J.-L. Gala et al., “Abnormal E-cadherin expression and prostate cell blood dissemination as markers of biological recurrence in cancer,” European Journal of Cancer, vol. 37, no. 12, pp. 1475–1481, 2001. View at Publisher · View at Google Scholar · View at Scopus
  31. M. E. Ray, R. Mehra, H. M. Sandler, S. Daignault, and R. B. Shah, “E-cadherin protein expression predicts prostate cancer salvage radiotherapy outcomes,” Journal of Urology, vol. 176, no. 4, pp. 1409–1414, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. B. Hegymegi-Barakonyi, D. Eros, C. Szántai-Kis et al., “Tyrosine kinase inhibitors—small molecular weight compounds Inhibiting EGFR,” Current Opinion in Molecular Therapeutics, vol. 11, no. 3, pp. 308–321, 2009. View at Google Scholar · View at Scopus
  33. S. Thomson, E. Buck, F. Petti et al., “Epithelial to mesenchymal transition is a determinant of sensitivity of non-small-cell lung carcinoma cell lines and xenografts to epidermal growth factor receptor inhibition,” Cancer Research, vol. 65, no. 20, pp. 9455–9462, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. R. L. Yauch, T. Januario, D. A. Eberhard et al., “Epithelial versus mesenchymal phenotype determines in vitro sensitivity and predicts clinical activity of erlotinib in lung cancer patients,” Clinical Cancer Research, vol. 11, no. 24, pp. 8686–8698, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. B. A. Frederick, B. A. Helfrich, C. D. Coldren et al., “Epithelial to mesenchymal transition predicts gefitinib resistance in cell lines of head and neck squamous cell carcinoma and non-small cell lung carcinoma,” Molecular Cancer Therapeutics, vol. 6, no. 6, pp. 1683–1691, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. Y. Haddad, W. Choi, and D. J. McConkey, “Delta-crystallin enhancer binding factor 1 controls the epithelial to mesenchymal transition phenotype and resistance to the epidermal growth factor receptor inhibitor erlotinib in human head and neck squamous cell carcinoma lines,” Clinical Cancer Research, vol. 15, no. 2, pp. 532–542, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. S. E. Witta, R. M. Gemmill, F. R. Hirsch et al., “Restoring E-cadherin expression increases sensitivity to epidermal growth factor receptor inhibitors in lung cancer cell lines,” Cancer Research, vol. 66, no. 2, pp. 944–950, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. D. Camenisch, A. P. Spicer, T. Brehm-Gibson et al., “Disruption of hyaluronan synthase-2 abrogates normal cardiac morphogenesis and hyaluronan-mediated transformation of epithelium to mesenchyme,” Journal of Clinical Investigation, vol. 106, no. 3, pp. 349–360, 2000. View at Google Scholar · View at Scopus
  39. A. Zoltan-Jones, L. Huang, S. Ghatak, and B. P. Toole, “Elevated hyaluronan production induces mesenchymal and transformed properties in epithelial cells,” Journal of Biological Chemistry, vol. 278, no. 46, pp. 45801–45810, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. Y. Xu and Q. Yu, “E-cadherin negatively regulates CD44-hyaluronan interaction and CD44-mediated tumor invasion and branching morphogenesis,” Journal of Biological Chemistry, vol. 278, no. 10, pp. 8661–8668, 2003. View at Publisher · View at Google Scholar · View at Scopus
  41. C. B. Knudson, “Hyaluronan receptor-directed assembly of chondrocyte pericellular matrix,” Journal of Cell Biology, vol. 120, no. 3, pp. 825–834, 1993. View at Publisher · View at Google Scholar · View at Scopus
  42. K. A. Peebles, J. M. Lee, J. T. Mao et al., “Inflammation and lung carcinogenesis: applying findings in prevention and treatment,” Expert Review of Anticancer Therapy, vol. 7, no. 10, pp. 1405–1421, 2007. View at Publisher · View at Google Scholar · View at Scopus
  43. T. Fukuyama, Y. Ichiki, S. Yamada et al., “Cytokine production of lung cancer cell lines: correlation between their production and the inflammatory/immunological responses both in vivo and in vitro,” Cancer Science, vol. 98, no. 7, pp. 1048–1054, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Wang, T. Wang, S. Liu, D. Yoshida, and A. Teramoto, “The expression of matrix metalloproteinase-2 and -9 in human gliomas of different pathological grades,” Brain Tumor Pathology, vol. 20, no. 2, pp. 65–72, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. A. F. Chambers and L. M. Matrisian, “Changing views of the role of matrix metalloproteinases in metastasis,” Journal of the National Cancer Institute, vol. 89, no. 17, pp. 1260–1270, 1997. View at Google Scholar · View at Scopus
  46. J. R. Grandis and J. C. Sok, “Signaling through the epidermal growth factor receptor during the development of malignancy,” Pharmacology and Therapeutics, vol. 102, no. 1, pp. 37–46, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. R. W. Akita and M. X. Sliwkowski, “Preclinical studies with erlotinib (Tarceva),” Seminars in Oncology, vol. 30, no. 3, pp. 15–24, 2003. View at Google Scholar · View at Scopus
  48. N. Normanno, C. Bianco, A. De Luca, and D. S. Salomon, “The role of EGF-related peptides in tumor growth,” Frontiers in Bioscience, vol. 6, pp. 685–707, 2001. View at Google Scholar · View at Scopus
  49. D. Matanić, Z. Beg-Zec, D. Stojanović et al., “Cytokines in patients with lung cancer,” Scandinavian Journal of Immunology, vol. 57, no. 2, pp. 173–178, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. Y. Hasegawa, S. Takanashi, Y. Kanehira, T. Tsushima, T. Imai, and K. Okumura, “Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinom,” Cancer, vol. 91, no. 5, pp. 964–971, 2001. View at Google Scholar
  51. A. Jacobson, J. Brinck, M. J. Briskin, A. P. Spicer, and P. Heldin, “Expression of human hyaluronan syntheses in response to external stimuli,” Biochemical Journal, vol. 348, no. 1, pp. 29–35, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. B. P. Toole, “Hyaluronan in morphogenesis,” Seminars in Cell and Developmental Biology, vol. 12, no. 2, pp. 79–87, 2001. View at Publisher · View at Google Scholar · View at Scopus
  53. M. G. Kris, R. B. Natale, R. S. Herbst et al., “Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial,” Journal of the American Medical Association, vol. 290, no. 16, pp. 2149–2158, 2003. View at Publisher · View at Google Scholar · View at Scopus
  54. F. A. Shepherd, J. R. Pereira, T. Ciuleanu et al., “Erlotinib in previously treated non-small-cell lung cancer,” The New England Journal of Medicine, vol. 353, no. 2, pp. 123–132, 2005. View at Publisher · View at Google Scholar · View at Scopus
  55. M. Fukuoka, S. Yano, G. Giaccone et al., “Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial),” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2237–2246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  56. M.-S. Tsao, A. Sakurada, J.-C. Cutz et al., “Erlotinib in lung cancer—molecular and clinical predictors of outcome,” The New England Journal of Medicine, vol. 353, no. 2, pp. 133–144, 2005. View at Publisher · View at Google Scholar · View at Scopus
  57. T. J. Lynch, D. W. Bell, R. Sordella et al., “Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib,” The New England Journal of Medicine, vol. 350, no. 21, pp. 2129–2139, 2004. View at Publisher · View at Google Scholar · View at Scopus
  58. S. Thomson, F. Petti, I. Sujka-Kwok, D. Epstein, and J. D. Haley, “Kinase switching in mesenchymal-like non-small cell lung cancer lines contributes to EGFR inhibitor resistance through pathway redundancy,” Clinical and Experimental Metastasis, vol. 25, no. 8, pp. 843–854, 2008. View at Publisher · View at Google Scholar · View at Scopus